DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for prostate adenocarcinoma — screening already-approved drugs against its 44-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleProstate adenocarcinoma maps to a 44-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for prostate adenocarcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 6A (KDM6A) — KDM6A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet e7zdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FUL · 1.649 Å · ligand 1-methyl-5-oxidanyl-4-oxidanylidene-pyridine-2-carboxylic acid (E7Z). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Urology · 2008 · 22 citations
Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate: An Exploratory Analysis Using Data From the CaPSURE Database
AbstractPURPOSE: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. MATERIALS AND METHODS: The CaPSURE registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36 and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. RESULTS: Of the 13,740 men enrolled in CaPSURE 608 (4.42%) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) or hormonal ablation (54%). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). CONCLUSIONS: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.
Magnetic resonance spectroscopy as a decision tool in multimodality treatment design for localised prostate cancer
AbstractPredicting the outcome of individual prostate adenocarcinoma can be challenging, especially for patients affected by intermediate or high risk, but localised disease. Natural histories of prostate cancers with similar stage and prognostic factors can differ significantly; and an ongoing debate surrounds the optimal treatment choice for men diagnosed with non-metastatic prostate cancer. A variety of effective therapeutic options are available to be used as a sole modality, or in combination, including surgery, external beam radiotherapy, brachytherapy, and endocrine manipulation. Although these treatments have been used routinely for more than 15 years, there is a paucity of data from randomised trials comparing their results. In addition, most treatment techniques have changed dramatically in the last two decades due to the ongoing healthcare technological revolution. The rapid proliferation of new and expensive therapeutic options (i.e. adaptive radiotherapy, focal ablation, etc.) promises to minimise treatment related side effects and improve local control, however, there is no uniform consensus. Treatment choice is based on the available prognostic factors and life expectancy, along with patient preference, toxicity profiles, the individual institution’s (and clinician’s) experience and resource availability. Unfortunately, our prognostic tools are still limited, as is our ability to precisely predict which subset of patients might benefit from more aggressive therapeutic combinations. Therefore, a significant number of patients receive unnecessary and expensive treatments, whilst others are denied highly technological procedures because of associated resource limitation. This paper aims to analyse the current evidence, cost-effectiveness and controversies, surrounding the nonsurgical treatment of localised prostate cancer, with a focus on radiation and endocrine therapies, and to discuss the role of magnetic resonance spectroscopy, as a decision tool for multimodality treatment design and prediction of response.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
